Upgrade to SI Premium - Free Trial

Rani Therapeutics (RANI)

0.83 0.00 (0.00%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (8/6/26)

Latest Headlines

Form 4 Rani Therapeutics Holdin For: Jun 03 Filed by: McKinley Kate June 5, 2026 6:20 PM - SEC Filing Form 4 Rani Therapeutics Holdin For: Jun 03 Filed by: Javadi Alireza June 5, 2026 6:18 PM - SEC Filing Form 4 Rani Therapeutics Holdin For: Jun 03 Filed by: Imran Talat June 5, 2026 6:15 PM - SEC Filing Form 4 Rani Therapeutics Holdin For: May 28 Filed by: Bassan Abraham June 1, 2026 4:11 PM - SEC Filing Form 4 Rani Therapeutics Holdin For: May 28 Filed by: Rometty Lisa Ann June 1, 2026 4:11 PM - SEC Filing Form 4 Rani Therapeutics Holdin For: May 28 Filed by: IMRAN MIR A June 1, 2026 4:10 PM - SEC Filing Form 4 Rani Therapeutics Holdin For: May 28 Filed by: BUTEL JEAN LUC June 1, 2026 4:09 PM - SEC Filing Form 4 Rani Therapeutics Holdin For: May 28 Filed by: Bailey Vasudev Jaiprakash June 1, 2026 4:09 PM - SEC Filing Form 4 Rani Therapeutics Holdin For: May 28 Filed by: Ausiello Dennis A June 1, 2026 4:09 PM - SEC Filing Form 8-K Rani Therapeutics Holdin For: May 28 May 29, 2026 6:03 AM - SEC Filing Form SCHEDULE 13D/A Rani Therapeutics Holdin Filed by: Samsara BioCapital, L.P. May 28, 2026 5:53 PM - SEC Filing Form 8-K Rani Therapeutics Holdin For: May 26 May 27, 2026 6:03 AM - SEC Filing Form 424B5 Rani Therapeutics Holdin May 27, 2026 6:03 AM - SEC Filing Rani Therapeutics prices $20 million stock offering at $1.07 per share May 26, 2026 8:01 AM - StreetInsider Rani Therapeutics Holdings, Inc. Announces Pricing of $20.0 Million Registered Direct Offering of Class A Common Stock Priced At-The-Market Under Nasdaq Rules May 26, 2026 8:00 AM - Globe NewsWire Canaccord Reiterates Buy Rating on Rani Therapeutics (RANI) May 20, 2026 6:26 AM - StreetInsider Form 10-Q Rani Therapeutics Holdin For: Mar 31 May 15, 2026 4:16 PM - SEC Filing Form 8-K Rani Therapeutics Holdin For: May 11 May 15, 2026 4:13 PM - SEC Filing NASDAQ:RANI reports Q1 2026 results, announces CFO departure May 15, 2026 4:05 PM - StreetInsider Rani Therapeutics Reports First Quarter 2026 Financial Results; Provides Corporate Update; Announces CFO Transition May 15, 2026 4:05 PM - Globe NewsWire Form SCHEDULE 13G/A Rani Therapeutics Holdin Filed by: SymBiosis Capital Partners, LLC May 15, 2026 11:32 AM - SEC Filing Rani Therapeutics to Participate in the H.C. Wainwright Annual BioConnect Investor Conference May 12, 2026 4:05 PM - Globe NewsWire Form SCHEDULE 13G Rani Therapeutics Holdin Filed by: VANGUARD CAPITAL MANAGEMENT LLC April 30, 2026 12:58 PM - SEC Filing Form ARS Rani Therapeutics Holdin For: Dec 31 April 16, 2026 4:51 PM - SEC Filing Form DEFA14A Rani Therapeutics Holdin April 16, 2026 4:49 PM - SEC Filing Form DEF 14A Rani Therapeutics Holdin For: May 28 April 16, 2026 4:47 PM - SEC Filing Lake Street Starts Rani Therapeutics (RANI) at Buy April 14, 2026 7:18 AM - StreetInsider Rani Therapeutics appoints Dr. Sara Kenkare-Mitra as strategic advisor April 9, 2026 7:03 AM - StreetInsider Rani Therapeutics Appoints Dr. Sara Kenkare-Mitra as Strategic Advisor to Advance Platform and Clinical Strategy April 9, 2026 7:00 AM - Globe NewsWire Rani Therapeutics (RANI) PT Lowered to $5 at Canaccord March 31, 2026 2:15 PM - StreetInsider Form 3 Rani Therapeutics Holdin For: Mar 18 Filed by: Javadi Alireza March 27, 2026 7:47 PM - SEC Filing Form SCHEDULE 13G/A Rani Therapeutics Holdin Filed by: VANGUARD GROUP INC March 27, 2026 11:34 AM - SEC Filing Form S-8 Rani Therapeutics Holdin March 26, 2026 4:47 PM - SEC Filing Form 10-K Rani Therapeutics Holdin For: Dec 31 March 26, 2026 4:45 PM - SEC Filing Rani Therapeutics Holdings, Inc. (RANI) Misses Q4 EPS by 2c March 26, 2026 4:36 PM - StreetInsider Form 8-K Rani Therapeutics Holdin For: Mar 26 March 26, 2026 4:11 PM - SEC Filing Rani Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Corporate Update March 26, 2026 4:05 PM - Globe NewsWire Rani Therapeutics names Jesper Høiland as head of strategy March 25, 2026 4:56 PM - StreetInsider Rani Therapeutics Appoints Jesper Høiland as Head of Strategy to Advance Corporate and Pipeline Prioritization March 25, 2026 4:53 PM - Globe NewsWire Rani Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results March 19, 2026 4:05 PM - Globe NewsWire Full Article List